Conshohocken, Pennsylvania-based Cencora, Inc. (COR) sources and distributes pharmaceutical products in the United States and internationally. Valued at a market cap of $68.5 billion, the company distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, and more.
Shares of Cencora have lagged behind the broader market over the past year, falling 1.8% compared to the S&P 500 Index’s ($SPX) 12.2% surge. Moreover, in 2026, the stock has grown by nearly 6.3%, also underperforming SPX’s 10.5% gain.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Zooming in further, the State Street Healthcare Select Sector SPDR ETF (XLV) has risen 23.6% over the past year, outperforming the stock. In 2026, XLV has surged 22% and outpaced the stock.
On Nov. 5, COR stock declined 4.1% following the release of its Q4 2026 earnings. The company’s revenue for the quarter rose 5.5% from the prior year’s quarter to $88.4 billion and came in line with the Street’s estimates. Moreover, its adjusted EPS amounted to $4.66, topping the consensus estimates. However, the company’s adjusted EPS guidance was $19.58 at the midpoint for fiscal 2027, which missed Wall Street’s forecasts, resulting in a loss of investor confidence.
For the current year, which ended in September, analysts expect COR’s EPS to rise 9% to $19.58 on a diluted basis. The company surpassed the consensus estimate in three of the last four quarters, while missing on one occasion.
Despite its underperformance over the past year, according to 14 analysts covering COR stock, the consensus is a “Strong Buy.” That’s based on 10 “Strong Buy” ratings and four “Holds.”
The configuration has grown more bearish over the past months, with the stock now having 10 “Strong Buy” ratings, as compared to 11 three months ago.
On Nov. 10, J.P. Morgan analyst Lisa Gill maintained a “Buy” rating for COR stock and raised its price target from $390 to $413.
COR’s mean price target of $380.69 offers an upside of 6% compared to the current market price. Its Street-high target of $414 implies a robust 15.3% upside from current levels.
On the date of publication, Aritra Gangopadhyay did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Cisco Systems Had a Stellar Quarter, But CSCO Tumbled - Is It Too Cheap Here? Down 62% From All-Time Highs, Here’s How to Play CRWV Stock as CoreWeave Smashes Q3 Estimates Demand for the Anthropic IPO Far Outpaces Available Shares. Be Careful in an Early Scramble for Stock. Option Volatility and Earnings Report For Nov 16-20